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Abstract 
Background: The United States and Canada are amidst an opioid overdose crisis, with the Canadian province of 
British Columbia (BC) among the hardest hit. In response, drug checking services (DCS) have been introduced in this 
setting as a novel pilot harm reduction intervention though little is known about usage rates. Therefore, we sought to 
identify factors associated with drug checking uptake among people who use drugs (PWUD) in Vancouver, BC.
Methods: Data were derived from three ongoing prospective cohort studies of PWUD in Vancouver between June 
and November 2018. Multivariable logistic regression was used to determine factors associated with self‑reported 
DCS utilization in the past 6 months among participants at high risk of fentanyl exposure (i.e., those self‑reporting 
illicit opioid use or testing positive for fentanyl via urine drug screen).
Results: Among 828 eligible participants, including 451 (55%) males, 176 (21%) reported recent use of DCS. In mul‑
tivariable analyses, factors significantly associated with DCS utilization included: homelessness (Adjusted Odds Ratio 
[AOR] 1.47; 95% Confidence Interval [CI] 1.01–2.13) and involvement in drug dealing (AOR 1.59; 95% CI 1.05–2.39).
Conclusions: In our sample of PWUD, uptake of DCS was low, although those who were homeless, a sub‑population 
known to be at a heightened risk of overdose, were more likely to use the services. Those involved in drug dealing 
were also more likely to use the services, which may imply potential for improving drug market safety. Further evalua‑
tion of drug checking is warranted.
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Introduction
An opioid overdose crisis continues to impact com-
munities across the United States and Canada. This is 
attributed in large part to the introduction of potent and 
illegally manufactured synthetic opioids into the illicit 
drug supply [1–4]. In 2018, there were 21.7 opioid over-
dose deaths per 100,000 population in the United States 
(US) and 12.4 deaths per 100,000 population in Canada 
[5, 6]. In the Canadian province of British Columbia (BC), 
one of the hardest hit regions, a public health emergency 
was declared in 2016 in response to the increase in ille-
gal drug overdose deaths [7, 8]. As part of the response, 
various interventions were implemented and scaled up, 
including widespread availability of naloxone and super-
vised consumption services. In 2019, the number of over-
dose deaths has finally declined compared to previous 
years; however, the rate of death from overdose remains 
unacceptably high [8]. In 2019, a fatal opioid overdose 
rate was 19.4 deaths per 100,000 individuals in BC [8].
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In this context, drug checking gained attention as a 
harm reduction intervention with potential to miti-
gate overdose risks. Drug checking services (DCS) seek 
to provide people who use drugs (PWUD) with per-
sonalized information on the chemical composition of 
their drugs and increase awareness of their exposure to 
harmful adulterants [9–12]. Historically, DCS have been 
implemented mostly in party and music festival settings 
around the world but have not been well deployed in 
other drug scenes [11–15]. Amidst an opioid overdose 
crisis, drug checking creates an opportunity to pro-
vide harm reduction education, counselling, and refer-
rals to other services (e.g., drug treatment), as well as 
monitor trends in the illicit drug supply market [9, 10]. 
In BC, DCS outside of party and music festival settings 
was introduced at Insite, a supervised injection facility 
(SIF) in Vancouver, in 2016 [7]. As described elsewhere 
[16], the drug-checking technologies used in this setting 
included fentanyl immunoassay strips in 2016 and the 
combination of Fourier-Transform Infrared (FTIR) Spec-
troscopy and fentanyl immunoassay strips since 2017. 
The FTIR is capable of identifying and quantifying a wide 
range of substances in mixture submitted for analysis, 
while the testing strips can qualitatively detect a low con-
centration of fentanyl presence in the drug sample [7, 11].
Despite the enthusiasm about drug checking, there is 
limited scientific evaluation of drug checking as a harm 
reduction intervention, specifically in the context of 
regular non-medical opioid use and outside of party and 
music festival settings. Available evidence paints a mixed 
picture. Emerging research from the US has suggested 
high levels of willingness to use drug checking among 
PWUD amidst the opioid overdose crisis and indicated 
that DCS may encourage them to adopt available harm 
reduction practices through increased awareness of 
adulterants, such as fentanyl [9, 10]. For example, a 2017 
study involving 334 street-based PWUD found that 85% 
of participants were interested in using drug check-
ing. Of those interested, 70% expressed that they would 
change their drug-using behaviors (e.g., discard drugs or 
dose reduction) if they knew their drug had fentanyl [10]. 
This was in line with findings of studies focusing on party 
and festival settings suggesting that many people whose 
drug samples tested positive for adulterants such as fen-
tanyl discarded their substances [13, 14, 17]. However, a 
study conducted at Insite in Vancouver found low utiliza-
tion of a pilot drug checking service using the test strips 
only, with only approximately 1% of visits to Insite result-
ing in the use of drug checking [18]. Among those sam-
ples tested positive for fentanyl pre-consumption, only 
11% planned to discard their drugs [18]. Findings from a 
qualitative study shed some light on possible reasons for 
the low uptake of DCS among this population, including 
time dedication (i.e., time to get drugs checked), a hesi-
tancy to give up drugs, and the accessibility of the ser-
vices (i.e., limited hours and locations of operation) [19].
Taken together, the literature suggests that there could 
be some crucial differences in the uptake and effect of 
drug checking across different drug-using populations 
and different settings. Therefore, this study sought to 
identify the prevalence of and factors associated with 




Data for this study was derived from three ongoing pro-
spective cohort studies of people who use drugs (PWUD) 
from Vancouver, Canada: the Vancouver Injection Drug 
Users Study (VIDUS), the AIDS Care Cohort to evalu-
ate Exposure to Survival Services (ACCESS), and the 
At-Risk Youth Study (ARYS). Detailed sampling and 
recruitment procedures for these cohorts have been 
described elsewhere [20–22]. In brief, VIDUS enrolls 
HIV-negative adults (≥ 18  years of age) who injected 
drugs in the month prior to enrolment; ACCESS enrolls 
HIV-positive adults who used illicit drugs other than or 
in addition to cannabis in the month before enrolment, 
and ARYS enrolls street-involved youth aged 14–26 years 
who used illicit drugs other than or in addition to can-
nabis in the month before enrolment. In all studies, the 
primary modes of recruitment were self-referral, word of 
mouth, and street outreach. Eligibility criteria included 
residing in the Greater Vancouver region and providing 
written informed consent. The study instruments and 
follow-up procedures, including the questionnaires, were 
harmonized to permit for pooled data analyses. At base-
line and semi-annually thereafter, participants completed 
an interviewer-administered questionnaire that elicited 
information about socio-demographic characteristics, 
drug use and other behavioral patterns and social/struc-
tural exposures. Additionally, participants completed a 
urine drug screen (UDS) using BTNX Rapid Response™ 
Multi-Drug Test Panel (Markham, ON, Canada). The 
procedure for UDS has been described elsewhere [23]. 
At the completion of each study visit, participants were 
provided with a $40 (CDN) honorarium. The cohort 
studies have received approvals from the University of 
British Columbia/Providence Health Care Research Eth-
ics Board.
Study sample and primary outcome measure
The present analysis is a cross-sectional study embed-
ded within the prospective cohort studies. The sam-
ple was restricted to individuals who completed a study 
visit between June and November 2018, as questions 
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related to DCS were added to the questionnaire during 
this period. The sample was further restricted to those 
who self-reported any illicit opioid use (i.e., heroin, non-
medical use of prescription opioids, or suspected use of 
fentanyl) in the past 6 months or tested positive for fen-
tanyl through the UDS at the time of the interview, and 
those who provided a valid answer to the question about 
the primary outcome. The primary outcome of interest 
was self-reported DCS utilization in the past 6  months 
(yes vs. no) and derived from the question: “Have you 
used any drug checking services in the last 6 months?” If 
responded “no”, participants were asked why they didn’t 
use drug checking services and provided with a list of 
options including, “Service wasn’t easily accessible to me 
(location, times, etc.)”, “Not interested in knowing what’s 
in my drugs”, “No point in getting my drugs checked, as 
I have no other alternates (e.g., there’s fentanyl in every-
thing, dope sick, desperate)”, “Other (i.e., an open-ended 
option)”, among other responses.
Study variables
We considered a range of explanatory variables, includ-
ing demographic, behavioral, and other socio-structural 
characteristics, that might be associated with DCS uti-
lization, based on known correlates of accessing other 
harm reduction services among this population [2, 
24–27]. Socio-demographic data included: self-identi-
fied gender (male vs. non-male); age (per year older); 
homelessness (yes vs. no); ethnicity/ancestry (white vs. 
non-white); and living in the Downtown Eastside neigh-
borhood (DTES) of Vancouver that is an epicenter of 
illicit drug use (yes vs. no). Drug use behavior variables 
were dichotomous (yes vs. no) and included: injection 
drug use; ≥ daily heroin use; ≥ daily non-medical use of 
prescription opioids; ≥ daily crystal methamphetamine 
use; ≥ daily benzodiazepine use; ≥ daily crack cocaine 
use; ≥ daily cocaine use; binge drug use; and non-fatal 
drug overdose. Other social and structural exposures 
included: incarceration (yes vs. no); and involvement in 
drug dealing (yes vs. no). All behavioral and social/struc-
tural variables were based on self-report and referred to 
the previous 6 months unless otherwise specified.
Statistical analysis
First, we used logistic regression to examine bivariable 
associations between the explanatory variables and the 
primary outcome variable. Then, we used an a priori- 
defined backward model selection procedure based on 
examination of Akaike Information Criterion (AIC) to 
fit a multivariable model [28]. In brief, we first included 
a full multivariable model with all explanatory variables 
that were significantly associated with the drug checking 
services utilization at p < 0.10 in the bivariable analyses, 
excluding injection drug use in the past 6  months due 
to the skewed distribution of responses (i.e., virtually all 
participants [94.9%] who used drug checking injected 
drugs in the past 6  months). After examining the AIC 
value of the model, we removed the variable with the 
largest p value and built a reduced model. We contin-
ued this iterative process and selected the multivariable 
model with the lowest AIC score. In a sub-analysis, we 
used descriptive statistics to examine self-reported rea-
sons for not having used drug checking services. All p 
values were two-sided. All statistical analyses were per-
formed using SAS, version 9.4 (SAS Institute Inc., Cary, 
NC, USA).
Results
A total of 828 individuals were eligible for the present 
study, of whom 451 (55%) reported being male, and 390 
(47%) being white. The median age of this sample was 
41.0 (quartile Q1–Q3 = 30.6–52.1) years. Of this sam-
ple, 176 (21%) reported DCS use in the past 6  months, 
of whom 93 (53%) were male, and almost all (167, 94.9%) 
reported injection drug use in the past 6 months. Char-
acteristics of the sample and the results of the bivariable 
logistic regression analyses are presented in Table 1.
Table  2 shows the results of the multivariable logistic 
regression analyses. Factors independently associated 
with DCS use included: homelessness (Adjusted Odds 
Ratio [AOR] 1.47; 95% confidence interval [CI] 1.01–
2.13), living in the DTES (AOR 1.68; 95% CI 1.14–2.47), 
recent involvement in drug dealing (AOR 1.59; 95% CI 
1.05–2.39) and at least daily crack use (AOR 0.40; 95% CI 
0.19–0.83).
As shown in Table  3, commonly reported reasons for 
not using DCS included “not interested in knowing the 
drug contents” (33%), “no alternatives (fentanyl in every-
thing, dope sick, desperate)” (24%), “unaware of service” 
(24%), and “service wasn’t easily accessible (location, 
times, etc.)” (13%).
Discussion
In our sample of PWUD at a high risk of fentanyl expo-
sure in Vancouver, we found that the uptake of DCS was 
low, with only one-in-five using the services in the past 
6  months. In multivariable analysis, those who lived in 
DTES, were homeless or were involved in drug dealing 
were more likely to use DCS, while those who used crack 
cocaine at least daily were less likely to use DCS. The 
most commonly reported reason for not using DCS was 
no interest in knowing the contents of the drug.
The low uptake of DCS identified by our study is dif-
ferent from a finding of a previous study in the US show-
ing a high willingness to use DCS among street-based 
samples of PWUD [10]. This confirms that willingness to 
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Table 1 Bivariable analyses of factors associated with recent use of DCS among PWUD in Vancouver (n = 828)
Characteristic Drug checking service use Odds ratio (95% CI) p value
Yes
n (%)
n = 176 (21.3%)
No
n (%)
n = 652 (78.7%)
Age (med, Q1–Q3) 39.5 (30.0–51.6) 41.3 (30.8–52.4) 1.00 (0.98–1.01) 0.577
Gender
 Male 93 (52.8) 358 (54.9) 1.03 (0.71–1.49) 0.896
 Non‑male 56 (31.8) 221 (33.9)
Ethnicity
 White 90 (51.1) 300 (46.0) 1.25 (0.89–1.75) 0.192
 Non‑White 83 (47.2) 346 (53.1)
Living in DTES*
 Yes 131 (74.4) 402 (61.7) 1.81 (1.25–2.65) 0.002
 No 45 (25.6) 250 (38.3)
Drug dealing*
 Yes 49 (27.8) 111 (17.0) 1.87 (1.26–2.75) 0.002
 No 127 (72.2) 539 (82.7)
Homelessness*
 Yes 62 (35.2) 158 (24.2) 1.71 (1.19–2.44) 0.003
 No 113 (64.2) 493 (75.6)
Incarceration*
 Yes 19 (10.8) 44 (6.7) 1.67 (0.93–2.90) 0.076
 No 157 (89.2) 607 (93.1)
Non‑fatal Overdose*
 Yes 38 (21.6) 106 (16.3) 1.42 (0.93–2.13) 0.101
 No 138 (78.4) 545 (83.6)
Binge drug use*†
 Yes 75 (42.6) 241 (37.0) 1.26 (0.90–1.77) 0.176
 No 101 (57.4) 410 (62.9)
Injection drug use*
 Yes 167 (94.9) 522 (80.1) 4.62 (2.43–9.97) < 0.001
 No 9 (5.1) 130 (19.9)
Daily Benzodiazepine use*†
 Yes 3 (1.7) 4 (0.6) 2.81 (0.55–12.87) 0.179
 No 172 (97.7) 645 (98.9)
≥ Daily crack use*†
 Yes 9 (5.1) 76 (11.7) 0.41 (0.19–0.79) 0.014
 No 167 (94.9) 576 (88.3)
≥ Daily cocaine use*†
 Yes 2 (1.1) 25 (3.8) 0.29 (0.05–0.98) 0.093
 No 174 (98.9) 627 (96.2)
≥ Daily heroin Use*†
 Yes 89 (50.6) 260 (39.9) 1.54 (1.10–2.16) 0.011
 No 87 (49.4) 392 (60.1)
≥ Daily methamphetamine use*†
 Yes 53 (30.1) 146 (22.4) 1.49 (1.03–2.16) 0.034
 No 123 (69.9) 506 (77.6)
≥ Daily non‑medical use of prescription opioids*†
 Yes 10 (5.7) 16 (2.5) 2.39 (1.03–5.30) 0.034
 No 166 (94.3) 636 (97.5)
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use DCS and the actual uptake of DCS are two very dif-
ferent measures. Our results of the sub-analysis suggest 
that low uptake of DCS may reflect both the high levels of 
penetration of fentanyl into the illicit drug market in our 
setting [16] as well as the limited awareness and availabil-
ity of this service during the study period. As a result of 
the current drug market and limited financial resources, 
people’s ability to obtain new drugs once their drugs test 
positive for adulterants is limited. Thus, people may not 
place a high value on DCS. However, we note that there 
are other harm reduction strategies (e.g., dose reduc-
tion, not using alone, using at an SCS or OPS) that could 
be used once DCS confirm the presence of fentanyl in 
a drug sample. In this regard, the use of FTIR may have 
some added value in fentanyl saturated markets because 
it can provide PWUD with the percentage of fentanyl 
in their drug samples. Future research should investi-
gate awareness and uptake of these other harm reduc-
tion strategies after the use of DCS. On the other hand, 
among those who did not use DCS in our sample, nearly 
one-fifth reported that they were unaware of the service, 
and some reported programmatic barriers to access the 
service (e.g., location, opening hours). Of note, during a 
large part of this study period, DCS were only operating 
at a single SIF in Vancouver with limited hours. It is also 
worth mentioning that there were more DCS available in 
the area after the study period. Although DCS is located 
mostly in SIFs and harm reduction centers people can 
come in and check their drugs without using SIF services 
as well. Therefore, ongoing monitoring of DCS uptake is 
needed as DCS sites expand.
Even though we observed the limited reach of DCS to 
PWUD in our setting, we also found that those who were 
homeless were more likely to use the service. This find-
ing suggests that the service in our setting have reached 
a sub-population at a particularly high risk of overdose 
[29–31]. This likely reflects that services have been pro-
vided in a low-threshold manner as it was housed in a SIF 
designed to serve socially marginalized populations [32]. 
Nevertheless, because the majority (72%) of fatal over-
doses were occurring inside private residences between 
2016 and 2017 [33], future research should investigate 
how DCS can reach PWUD who use drugs alone at home 
as well.
Our study revealed a positive association between 
drug dealing and DCS use. This is consistent with pre-
vious research showing that people who had recently 
been involved in drug dealing were more likely to be 
willing to use DCS [34]. Drug dealers can play an essen-
tial role in reducing drug-related harms for PWUD 
through information sharing with their clients regard-
ing the content of their drugs. Previous qualitative 
Table 1 (continued)
CI, confidence interval; DTES, downtown eastside; Q, quartile; med, median
* Denotes activities/events in the past 6 months
† Refers to any route of consumption (i.e., sniffing, snorting, smoking or injecting)
Table 2 Multivariable logistic regression analyses 
of factors associated with recent use of DCS among PWUD 
(n = 828)
DTES, downtown eastside
* Denotes activities/events in the past 6 months










 (Yes vs. No) 1.68 (1.14–2.47) 0.009
Drug dealing*
 (Yes vs. No) 1.59 (1.05–2.39) 0.027
Homelessness*
 (Yes vs. No) 1.47 (1.01–2.13) 0.042
≥ Daily cocaine use*†
 (Yes vs. No) 0.26 (0.06–1.15) 0.075
≥ Daily crack use*†
 (Yes vs. No) 0.40 (0.19–0.83) 0.014
≥ Daily heroin use*†
 (Yes vs. No) 1.35 (0.95–1.91) 0.095
≥ Daily non‑medical 
use of prescription 
opioids*†
 (Yes vs. No) 2.35 (0.98–5.60) 0.055
Table 3 Self-reported reasons for not using drug checking 
services among PWUD in Vancouver (n = 665)
* Refers to any type of drug
Participants could provide more than one response
Reasons N %
Not interested in knowing the drug contents* 220 33.1
No alternatives (fentanyl in everything, dope sick, desperate) 159 23.9
Unaware of service 157 23.6
Service wasn’t easily accessible (location, times, etc.) 83 12.5
Use known source/dealer 17 2.6
Rarely use drugs 10 1.5
Use stimulants 3 0.5
Plan to use drug checking 3 0.5
Other 13 2.0
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research reported that PWUD were less likely to use 
DCS when they had an established relationship with 
drug dealers [24]. This comes with an underlying 
assumption that drug dealers know the content of the 
drugs they are selling, and their willingness to share 
the information with their clients. However, due to the 
inconsistent nature of the drug market in our setting, it 
is unlikely that street-level dealers accurately know the 
content of their drugs. Moreover, participants in our 
study are more likely to be street-level dealers. To make 
big impact, we would need to get at the supplier or 
distribution level dealers. Nevertheless, the ability for 
street-level dealers to utilize DCS to check their drugs 
before selling still has potential indirect benefits to 
PWUD as a harm reduction measure to prevent drug-
related harms (e.g., overdose). Further engagement and 
research with different levels of drug dealers in drug 
checking may be warranted to improve the DCS design, 
delivery and effectiveness.
Finally, we found that those who frequently used 
crack cocaine were less likely to use DCS. These find-
ings suggest a possible association between the pre-
ferred substance type (opioids vs. stimulants) and the 
uptake of DCS. Results from the British Columbia Cen-
tre on Substance Use’s provincial drug checking reports 
[35–40] show that the proportion of stimulants submit-
ted for drug checking was low compared to opioids. Of 
all the stimulant samples tested, less than one percent 
tested positive for fentanyl compared to 88% for opioid 
samples [35–40]. The low uptake of DCS among fre-
quent stimulant users might reflect a perceived low risk 
of fentanyl exposure in stimulants compared to opioids. 
However, when a stimulant drug is mixed with fentanyl, 
opioid-naïve stimulant users are at a heightened risk of 
overdose due to low tolerance [41] as well as the lack 
of awareness of fentanyl presence in their drugs. As 
such, providing accurate information to stimulant users 
regarding the contents of their drugs via DCS could 
play a critical role in reducing overdose risk. There-
fore, expanding the DCS to non-opioid users may be 
required [41, 42].
Limitations
There are several limitations to this study. First, data from 
our study were collected from non-random samples of 
PWUD, and therefore may not be generalizable to other 
populations of PWUD. Second, except for UDS screens, 
data were collected using self-reported information and 
thus is subject to reporting biases, including recall bias 
and socially desirable responding. Finally, it is impossible 
to determine the temporality between the outcome and 
explanatory variables from this cross-sectional study.
Conclusions
In summary, the recent use of DCS was low among our 
sample of PWUD at a high risk of fentanyl exposure. 
However, it appears to have reached sub-populations 
at a heightened risk of overdose, including those who 
were homeless. Moreover, people who were involved in 
drug dealing were more likely to use DCS, which may 
imply the potential for improving drug market safety. 
Findings also revealed that stimulant users were less 
likely to use DCS, suggesting further engagement with 
stimulant users is warranted in future planning for DCS 
implementation. As DCS continue to evolve, further 
evaluation of DCS is needed.
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